Abstract
Multisystemic inflammation might be a key pathophysiologic mechanism in post-coronavirus disease 2019 (post-COVID) syndrome. N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)5,7dimethylpyrazolo[1,5a] pyrimidin-3-yl)acetamide ([18F]DPA-714), which binds with high affinity the translocator protein (TSPO) receptor, is used as a marker of inflammation. Therefore, quantifying [18F]DPA-714 uptake throughout the body could assess extracerebral inflammation in post-COVID syndrome. However, the pharmacokinetics of whole-body [18F]DPA-714 uptake have not yet been assessed. Thus, before quantifying whole-body [18F]DPA-714 uptake in post-COVID syndrome, the aim of this study was to identify the optimal pharmacokinetic model in different extracerebral organs. Methods: Thirty-nine post-COVID participants with high-affinity binding for TSPO with or without persistent complaints were enrolled from the prospective VeCosCO study. Whole-body dynamic [18F]DPA-714 PET/CT scans (0-60 min after injection) were performed. Ascending aorta-based image-derived input functions were corrected with manual arterial blood samples to establish metabolite-corrected plasma input functions. Time-activity curves were derived from volumes of interest in the adrenal gland, bone, kidney, liver, lung, myocardium, pancreas, skeletal muscle, spleen, and thyroid. [18F]DPA-714 kinetics were studied by nonlinear regression fitting of 1- and 2-tissue-compartment models with an additional blood volume parameter to the time-activity curves. Results: An irreversible single-tissue-compartment model was preferred in bone and skeletal muscle, a reversible 2-tissue-compartment model was preferred in kidney and lung, and a reversible single-tissue-compartment model was preferred in the other organs. Our results showed various levels of [18F]DPA-714 uptake in the 10 extracerebral organs. The highest mean volume of distribution was found in myocardium (33.27 ± 11.91 mL⋅cm-3), and the lowest mean volume of distribution was found in lung (5.12 ± 2.85 mL⋅cm-3). The mean influx rate was higher in bone than in skeletal muscle (respectively, 0.101 vs. 0.052 mL⋅cm-3⋅min-1; P < 0.001). Conclusion: The TSPO receptor is widely distributed over the entire body, with very high [18F]DPA-714 uptake in several organs. An irreversible model in bone and skeletal muscle and a reversible model in the other organs were preferred to describe [18F]DPA-714 kinetics. Further studies using [18F]DPA-714 to assess extracerebral inflammation should consider these kinetic differences among TSPO-rich organs.
| Original language | English |
|---|---|
| Pages (from-to) | 1142-1148 |
| Number of pages | 7 |
| Journal | Journal of nuclear medicine |
| Volume | 66 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 1 Jul 2025 |
Keywords
- PET/CT
- [18F]DPA-714
- dynamic PET
- long axial field of view
- tracer kinetic modeling
Fingerprint
Dive into the research topics of 'Whole-Body [18F]DPA-714 Kinetic Assessment Using PET/CT Scanner with Long Axial Field of View'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver